IL-1 Receptor Antagonist
Pregnancy: B
Anakinra
Brand names: Kineret
Adult dose
Dose: 100 mg SC once daily
Route: subcutaneous injection
Frequency: once daily
Max: 100 mg/day
Pre-filled syringe with 27-gauge needle; rotate injection sites; refrigerate at 2–8°C; use within 30 min of removing from fridge
Paediatric dose
Dose: 1 mg/kg
Route: subcutaneous
Frequency: once daily
Max: 8 mg/kg/day (sJIA)
Concentration: 150 mg/mL mg/ml
sJIA: 1–2 mg/kg once daily SC (max 100 mg); NOMID/DIRA: higher doses; Cryopyrin-associated periodic syndrome
Dose adjustments
Renal
Reduce to every other day if eGFR <30 ml/min
Hepatic
No dose adjustment required
Paediatric weight-based calculator
sJIA: 1–2 mg/kg once daily SC (max 100 mg); NOMID/DIRA: higher doses; Cryopyrin-associated periodic syndrome
Clinical pearls
- Short half-life (4–6h) — daily injection required; high injection site reaction rate limits long-term adherence
- Preferred for CAPS, DIRA, sJIA flares, adult-onset Still's disease, and macrophage activation syndrome
- ANAJUSS study: effective in COVID-19 hyperinflammation (IL-1 pathway implicated)
Contraindications
- Active infections (especially sepsis)
- Neutropenia (ANC <1.5 × 10⁹/L)
- Live vaccines
Side effects
- Injection site reactions (60–75% — most common)
- Infections (serious bacterial)
- Neutropenia
- Thrombocytopenia
- Headache
Interactions
- TNF inhibitors (avoid — ANAKINRA trial: no additional benefit, threefold serious infections)
- Live vaccines (CI)
Monitoring
- FBC with neutrophil count (monthly × 3 months, then quarterly)
- Signs of infection
- Injection site reactions
Reference: BNFc; BNF 86; NICE TA71; BSR biologics guidelines. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022